OBJECTIVE: This study aimed to describe the relative and excess risk of pancreatic neuroendocrine tumor (NET) at least 6 months after the first primary cancer (FPC) among the US population. METHODS: Surveillance, Epidemiology, and End-Results Program data were analyzed for patients diagnosed as having FPC from 2000 to 2015 (n = 4,008,092). Standardized incidence ratios, excess risk, and average time to diagnosis of a second primary pancreatic NET were reported by FPC site, stratified by sex and receipt of radiotherapy and chemotherapy. RESULTS: Risk of pancreatic NET was significantly higher after FPC at any site, any solid tumor (standardized incidence ratios, 1.3; 95% confidence interval, 1.2-1.5), pancreas, thymus, small intestine, liver, stomach, kidney, lung, and female breast. Excess incidence of pancreatic NET was highest among those with FPC (especially NET) of the pancreas, bladder, thymus, and female breast; those who received radiotherapy/chemotherapy for bladder, melanoma, and stomach cancers; and those who received chemotherapy for uterine, cervical, prostate, and other genital cancers. Time to diagnosis was shortest after pancreatic, liver, lung, and stomach cancer. CONCLUSIONS: Cancer survivors have increased risk and excess incidence of primary pancreatic NET compared with the population, particularly for certain primary sites. High-risk patients should receive regular follow-up screenings, counseling to reduce carcinogen exposure, and lifestyle interventions.
OBJECTIVE: This study aimed to describe the relative and excess risk of pancreatic neuroendocrine tumor (NET) at least 6 months after the first primary cancer (FPC) among the US population. METHODS: Surveillance, Epidemiology, and End-Results Program data were analyzed for patients diagnosed as having FPC from 2000 to 2015 (n = 4,008,092). Standardized incidence ratios, excess risk, and average time to diagnosis of a second primary pancreatic NET were reported by FPC site, stratified by sex and receipt of radiotherapy and chemotherapy. RESULTS: Risk of pancreatic NET was significantly higher after FPC at any site, any solid tumor (standardized incidence ratios, 1.3; 95% confidence interval, 1.2-1.5), pancreas, thymus, small intestine, liver, stomach, kidney, lung, and female breast. Excess incidence of pancreatic NET was highest among those with FPC (especially NET) of the pancreas, bladder, thymus, and female breast; those who received radiotherapy/chemotherapy for bladder, melanoma, and stomach cancers; and those who received chemotherapy for uterine, cervical, prostate, and other genital cancers. Time to diagnosis was shortest after pancreatic, liver, lung, and stomach cancer. CONCLUSIONS:Cancer survivors have increased risk and excess incidence of primary pancreatic NET compared with the population, particularly for certain primary sites. High-risk patients should receive regular follow-up screenings, counseling to reduce carcinogen exposure, and lifestyle interventions.
Authors: Lois B Travis; Charles S Rabkin; Linda Morris Brown; James M Allan; Blanche P Alter; Christine B Ambrosone; Colin B Begg; Neil Caporaso; Stephen Chanock; Angela DeMichele; William Douglas Figg; Mary K Gospodarowicz; Eric J Hall; Michie Hisada; Peter Inskip; Ruth Kleinerman; John B Little; David Malkin; Andrea K Ng; Kenneth Offit; Ching-Hon Pui; Leslie L Robison; Nathaniel Rothman; Peter G Shields; Louise Strong; Toshiyasu Taniguchi; Margaret A Tucker; Mark H Greene Journal: J Natl Cancer Inst Date: 2006-01-04 Impact factor: 13.506
Authors: Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng Journal: Nat Rev Clin Oncol Date: 2013-03-26 Impact factor: 66.675
Authors: L Moonen; H vd Voet; R de Nijs; S Horenblas; A A Hart; H Bartelink Journal: Int J Radiat Oncol Biol Phys Date: 1998-10-01 Impact factor: 7.038
Authors: Sam Behjati; Gunes Gundem; David C Wedge; Nicola D Roberts; Patrick S Tarpey; Susanna L Cooke; Peter Van Loo; Ludmil B Alexandrov; Manasa Ramakrishna; Helen Davies; Serena Nik-Zainal; Claire Hardy; Calli Latimer; Keiran M Raine; Lucy Stebbings; Andy Menzies; David Jones; Rebecca Shepherd; Adam P Butler; Jon W Teague; Mette Jorgensen; Bhavisha Khatri; Nischalan Pillay; Adam Shlien; P Andrew Futreal; Christophe Badie; Ultan McDermott; G Steven Bova; Andrea L Richardson; Adrienne M Flanagan; Michael R Stratton; Peter J Campbell Journal: Nat Commun Date: 2016-09-12 Impact factor: 14.919
Authors: Mike Wenzel; Luigi Nocera; Christoph Würnschimmel; Claudia Collà Ruvolo; Zhe Tian; Fred Saad; Alberto Briganti; Derya Tilki; Markus Graefen; Andreas Becker; Frederik C Roos; Felix K H Chun; Pierre I Karakiewicz Journal: Front Oncol Date: 2021-10-06 Impact factor: 6.244